ARID5B

Across TCGA pan-cancer cohorts, ARID5B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARID5B data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARID5B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARID5B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

UCEC and GBM are the cancer types where ARID5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.376	1.000	.013	24	view →
GBM	OS	Median	All	0.680	0.370	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ARID5B–UCEC (DFS)

Open the UCEC breakdown →